This document serves to update the policy brief Injection safety in the context of coronavirus disease (COVID-19) vaccination (IS Policy Brief), with additional guidance. The IS Policy Brief remains valid and highlights the overall importance of reinforcing injection safety in the context of the pandemic, especially considering the significant resulting increase in the number of injections being administered worldwide.
This Addendum confirms that substituting syringes with re-use prevention features (RUP) for auto-disable (AD) syringes may exceptionally be necessary to address shortages of 0.3 ml AD syringes. In addition to the shortages of this specialty size, this Addendum to the IS Policy Brief further acknowledges compounding factors that will exacerbate availability challenges of AD syringes for some COVID-19 vaccines. In particular, some dosing regimens now call for non-standard dose volumes that do not correspond to any existing size of AD syringes.
Topic references
COVAX-PFIZER
Title | Author | Year | Type | Language |
Capacitación sobre la manipulación, el almacenamiento y el transporte de la vacuna Pfizer-BioNTech contra la COVID-19 ARNm COMIRNATY® (Tozinameran) | World Health Organization (WHO), UNICEF | 2021 | Training | Spanish |
COVID-19 Vaccine Rollout Technical brief delivery strategies options | COVAX Partners | 2021 | Presentation | English |
Formação sobre manuseamento, armazenamento e transporte da Vacina mRNA contra a COVID-19 Pfizer-BioNTech COMIRNATY® (Tozinameran) | World Health Organization (WHO), UNICEF | 2021 | Training | Portuguese |
Formation sur la manipulation, le stockage et le transport du vaccin Pfizer BioNTech COVID-19 | OMS - Organisation Mondiale de la Santé, UNICEF | 2021 | Training | French |
Injection safety in the context of coronavirus disease (COVID-19) vaccination | World Health Organization (WHO) | 2022 | Report | English |
Options de stratégies d'administration du vaccin COVID-19 | COVAX Partners | 2021 | Presentation | French |
Training on handling, storing and transporting Pfizer BioNTech COVID-19 Vaccine COMIRNATY® (Tozinameran) | World Health Organization (WHO), UNICEF | 2021 | Training | English |
Training on Pfizer‒BioNTech COVID-19 mRNA Vaccine COMIRNATY® (Tozinameran) - Updated 5 October 2021 | Gavi, the Vaccine Alliance, UNICEF, World Health Organization (WHO) | 2021 | Training | English |
Обучающий курс по хранению, транспортировке и обращению с мРНК-вакциной от COVID-19 COMIRNATY® (Tozinameran) производства компании Pfizer BioNTech | World Health Organization (WHO), UNICEF | 2021 | Training | Russian |
دورة تدريبية بشأن التعامل مع لقاح فايزر-بيونتيك المضاد لكوفيد-19 وطريقة تخزينه ونقله | COVAX Partners | 2021 | Training | Arabic |
Added by: Moderator
Added on: 2022-04-29 10:31:01
Hits: 517